BAM
CLDX icon

Brave Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Brave Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-67
Closed -$4K – 182
2016
Q3 		$4K Buy
67
+34
+103% +$2.12K ﹤0.01% 358
2016
Q2 		$2K Hold
33
– – ﹤0.01% 380
2016
Q1 		$2K Hold
33
– – ﹤0.01% 403
2015
Q4 		$8K Buy
+33
New +$7.19K 0.01% 364

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brave Asset Management's CLDX Position: Q4 2016 in Review

Brave Asset Management sold out of Celldex Therapeutics (CLDX) in Q4 2016, closing a stake of 67 shares — an estimated $4K sold.

Brave Asset Management first reported a position in CLDX in Q4 2015 and held it in 4 quarters. The position peaked at $8K in Q4 2015. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • Brave Asset Management reported no remaining Celldex Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Brave Asset Management sold 67 Celldex Therapeutics shares in Q4 2016, an estimated $4K.
  • Brave Asset Management first reported a position in Celldex Therapeutics in Q4 2015 and held it in 4 quarters.
  • Brave Asset Management's Celldex Therapeutics position peaked at $8K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on Brave Asset Management's 13F filing for Q4 2016, filed 27 Jan 2017.